Joanne B. Weidhaas
Affiliations: | Radiation Oncology | Yale University School of Medicine, New Haven, CT |
Google:
"Joanne Weidhaas"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Weidhaas JB. (2020) Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. Methods in Molecular Biology (Clifton, N.J.). 2055: 203-212 |
| Jung SY, Malhotra P, Nguyen KC, et al. (2019) The KRAS-variant and its impact on normal breast epithelial cell biology. Cell Death and Differentiation |
| Malhotra P, Read GH, Weidhaas JB. (2019) Breast Cancer and miR-SNPs: The Importance of miR Germ-Line Genetics. Non-Coding Rna. 5 |
| Yuan Y, Weidhaas JB. (2019) Functional microRNA binding site variants. Molecular Oncology. 13: 4-8 |
| Weidhaas JB, Scheffler AW, Salzman D, et al. (2019) A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy. Journal of Clinical Oncology. 37: 96-96 |
| Hui P, Gysler SM, Uduman M, et al. (2018) MicroRNA Signatures Discriminate Between Uterine and Ovarian Serous Carcinomas. Human Pathology |
| Weidhaas JB, Wilenius K, Scheffler AW, et al. (2018) A microRNA-based signature predicting immune-related toxicity (iRAEs) to pembrolizumab in prostate cancer patients. Journal of Clinical Oncology. 36: 269-269 |
| Mehta AK, Hua K, Whipple W, et al. (2017) Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Science Signaling. 10 |
| McVeigh TP, Mulligan RJ, McVeigh UM, et al. (2017) Investigating the association of rs2910164 with cancer in Irish patients. Endocrine Connections |
| Weidhaas JB, Telesca D, Kalbasi A, et al. (2017) Germ-line biomarkers disrupting microRNA regulatory pathways to predict toxicity and response to anti-PD-1 and anti-PD-L1 therapies. Journal of Clinical Oncology. 35: 3040-3040 |